Clinical characteristics of patients undergoing RPFNA
| A. Patient characteristics for RPFNA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Women enrolled in study | 38 | |||||||||
| Bilateral RPFNA | 28 | |||||||||
| Unilateral RPFNA | 10 | |||||||||
| RPFNA samples collected | 66 | |||||||||
| No. RPFNAs with insufficient epithelial cell count | 10 | |||||||||
| No. RPFNAs submitted for analysis | 56 | |||||||||
| n = 38 (%) | ||||||||||
| Average age and range (y) | 46 (29-64) | |||||||||
| Race | ||||||||||
| Caucasian | 33 (87) | |||||||||
| African American | 5 (13) | |||||||||
| Menopausal status | ||||||||||
| Postmenopausal | 18 (47) | |||||||||
| Premenopausal/Perimenopausal | 20 (53) | |||||||||
| Hormone replacement use | ||||||||||
| Current | 2 (5) | |||||||||
| Ever use | 9 (24) | |||||||||
| Never use | 27 (71) | |||||||||
| Antiestrogen therapy (at the time of RPFNA) | ||||||||||
| Tamoxifen | 2 (5) | |||||||||
| Raloxifene | 1 (3) | |||||||||
| Aromatase inhibitor | 2 (5) | |||||||||
| Family history of breast cancer | 17 (45) | |||||||||
| Prior abnormal biopsies | ||||||||||
| LCIS | 1 (3) | |||||||||
| DCIS | 5 (13) | |||||||||
| ADH | 10 (26) | |||||||||
| History of contralateral breast cancer | 5 (13) | |||||||||
| B. Characteristics of patients on prevention therapy at time of RPFNA | ||||||||||
| RPFNA sampling | Agent | Duration | Masood | Cell count | M3/M4 methylation | |||||
| Unilateral | Tamoxifen | 2 wk | 14 | 500 | +/+ | |||||
| Bilateral (L) | Raloxifene | 2 y | 10 | <10 | −/− | |||||
| Bilateral (R) | 10 | 10 | −/− | |||||||
| Unilateral | Tamoxifen | 2 wk | 15 | 1,000 | +/− | |||||
| Unilateral | Aromatase inhibitor | 1 y | NA | NA | −/− | |||||
| Unilateral | Aromatase inhibitor | 1 y | NA | NA | −/− | |||||